Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab) ; day:1 ; month:9 ; year:2016 ; pages:1-19
Advances in therapy ; (1.9.2016), 1-19
- Creator
-
Derzi, Mazin
- Contributor
-
Johnson, Theodore R.
Shoieb, Ahmed M.
Conlon, Hugh D.
Sharpe, Penny
Saati, Andrew
Koob, Sarah
Bolt, Michael W.
Lorello, Leslie G.
McNally, Jim
Kirchhoff, Carol F.
Smolarek, Teresa A.
Leach, Michael W.
SpringerLink (Online service)
- DOI
-
10.1007/s12325-016-0403-9
- URN
-
urn:nbn:de:1111-201609301962
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Derzi, Mazin
- Johnson, Theodore R.
- Shoieb, Ahmed M.
- Conlon, Hugh D.
- Sharpe, Penny
- Saati, Andrew
- Koob, Sarah
- Bolt, Michael W.
- Lorello, Leslie G.
- McNally, Jim
- Kirchhoff, Carol F.
- Smolarek, Teresa A.
- Leach, Michael W.
- SpringerLink (Online service)
Other Objects (12)
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Development of pulmonary sarcoidosis in Crohn’s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review
A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers
Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database
A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Development of pulmonary sarcoidosis in Crohn’s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review
A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers
Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database
A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Development of pulmonary sarcoidosis in Crohn’s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review
A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers
Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database
A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar